Mucosal Interleukin-10 depletion in steroid-refractory Crohn's disease patients.

Autor: Carrasco A; Department of Gastroenterology, Hospital Universitari Mútua Terrassa, Universitat de Barcelona, Catalonia, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Madrid, Spain., Tristán E; Department of Gastroenterology, Hospital Universitari Mútua Terrassa, Universitat de Barcelona, Catalonia, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Madrid, Spain., Fernández-Bañares F; Department of Gastroenterology, Hospital Universitari Mútua Terrassa, Universitat de Barcelona, Catalonia, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Madrid, Spain., Martín-Cardona A; Department of Gastroenterology, Hospital Universitari Mútua Terrassa, Universitat de Barcelona, Catalonia, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Madrid, Spain., Aceituno M; Department of Gastroenterology, Hospital Universitari Mútua Terrassa, Universitat de Barcelona, Catalonia, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Madrid, Spain., Zabana Y; Department of Gastroenterology, Hospital Universitari Mútua Terrassa, Universitat de Barcelona, Catalonia, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Madrid, Spain., Fluvià L; Proteomics and Metabolomics Core Facility, Institut de Recerca Germans Trias i Pujol (IGTP), Badalona, Spain., Hernández JM; Proteomics and Metabolomics Core Facility, Institut de Recerca Germans Trias i Pujol (IGTP), Badalona, Spain., Lorén V; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Madrid, Spain.; Research Group in Inflammatory Bowel Diseases, Institut de Recerca Germans Trias i Pujol (IGTP), Badalona, Spain., Manyé J; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Madrid, Spain.; Research Group in Inflammatory Bowel Diseases, Institut de Recerca Germans Trias i Pujol (IGTP), Badalona, Spain., Salas A; Department of Pathology, Hospital Universitari Mutua Terrassa, Universitat de Barcelona, Catalonia, Spain., Andújar X; Department of Gastroenterology, Hospital Universitari Mútua Terrassa, Universitat de Barcelona, Catalonia, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Madrid, Spain., Loras C; Department of Gastroenterology, Hospital Universitari Mútua Terrassa, Universitat de Barcelona, Catalonia, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Madrid, Spain., Esteve M; Department of Gastroenterology, Hospital Universitari Mútua Terrassa, Universitat de Barcelona, Catalonia, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Madrid, Spain.
Jazyk: angličtina
Zdroj: Immunity, inflammation and disease [Immun Inflamm Dis] 2022 Oct; Vol. 10 (10), pp. e710.
DOI: 10.1002/iid3.710
Abstrakt: Background: Previous studies suggested that Interleukin-10 (IL-10) depletion in Crohn's disease (CD) could predict outcome.
Aim: To determine IL-10 in blood and at different intestinal locations in patients with active CD and to assess its potential prognostic capacity to identify aggressive CD.
Methods: Twenty-three patients with CD were included. Ulcerative colitis (UC), infectious colitis and healthy individuals acted as controls. Serum and mucosal samples were taken at baseline and 1 month after steroid initiation in CD patients. Patients were classified according to steroid response. Control samples were obtained from different intestinal locations. IL-10 expression was measured with real-time polymerase chain reaction, immunofluorescence (intestine) and ELISA (serum, biopsy cultures' supernatants and tissue homogenates).
Results: CD and UC showed an increase in IL-10 messenger RNA (mRNA) versus controls (p < .0001) in mucosa, whereas IL-10 protein secretion was increased in all types of intestinal inflammation (p < .001). No differences in IL-10 mRNA were found in CD at baseline regarding steroid response, but levels decreased in non-responders versus responders (p = .027) and were restored with rescue therapy. Serum IL-10 was increased in steroid-refractory CD at baseline and after treatment.
Conclusions: Abnormal IL-10 levels in refractory patients in both mucosa and blood have physiopathological relevance and may have potential clinical applications.
(© 2022 The Authors. Immunity, Inflammation and Disease published by John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje